(Q34529575)

2 August 2017

1 reference

title

Adjuvant interferon-alpha for melanoma revisited: news from old and new studies (English)

1 reference

2 August 2017

2

A M Eggermont

0 references

author name string

C J Punt

series ordinal

1

1 reference

PubMed ID

11843241

2 August 2017

A M Eggermont

series ordinal

2

1 reference

2 August 2017

1 December 2001

1 reference

2 August 2017

1 reference

2 August 2017

12

1 reference

2 August 2017

1663-1666

1 reference

2 August 2017

12

1 reference

A new American Joint Committee on Cancer staging system for cutaneous melanoma

2 August 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013592219007

7 January 2021

The AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013592219007

7 January 2021

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013592219007

7 January 2021

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013592219007

7 January 2021

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013592219007

7 January 2021

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013592219007

7 January 2021

Results of adjuvant interferon study in WHO melanoma programme

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013592219007

7 January 2021

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013592219007

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013592219007

7 January 2021

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013592219007

7 January 2021

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013592219007

7 January 2021

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013592219007

7 January 2021

Identifiers

DOI

10.1023/A:1013592219007

1 reference

2 August 2017

1 reference

PubMed ID

11843241